A simple and rapid HPLC-MS/MS method for therapeutic drug monitoring of amikacin in dried matrix spots.

This study focuses on a simple and rapid hplc-ms/ms method for therapeutic drug monitoring of amikacin in dried matrix spots.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the clinical field. Individualized treatment of amikacin under the guidance of therapeutic drug monitoring (TDM) is important to reduce the occurrence of toxicity and improve clinical efficacy. In the present study, we developed and validated a simple and high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine the concentration of amikacin in dried... Research Background and Significance Therapeutic drug monitoring (TDM) plays an essential role in the individualized treatment of drugs with narrow therapeutic windows, such as amikacin, an aminoglycoside antibiotic widely used to treat severe bacterial infections. Precise quantification of amikacin concentrations in patients’ biological samples is critical to optimize dosing regimens, minimize toxicity, and improve clinical outcomes. Traditional plasma or serum sampling methods, however, pose logistical challenges and often require complex sample processing. The emergence of dried matrix spots (DMS) as an alternative sampling format offers significant advantages in sample collection, storage, and transport, especially in clinical settings with limited infrastructure. This study by Chen et al. addresses the urgent need for a rapid, sensitive, and robust analytical method to quantify amikacin in DMS, leveraging high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). The development of such a method facilitates effective TDM, enhancing therapeutic efficacy while mitigating nephrotoxicity and ototoxicity risks associa